Fariba Ahmadizar1, Carolina Ochoa-Rosales1,2, Marija Glisic1,3, Oscar H Franco1,4, Taulant Muka1,4, Bruno H Stricker1,5. 1. Department of Epidemiology, Erasmus University Medical Centre, Rotterdam, The Netherlands. 2. Centro de Vida Saludable de la Universidad de Concepción, Concepción, Chile. 3. Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany. 4. Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland. 5. Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Abstract
AIMS: There are several epidemiological studies on the association between statins and incident diabetes, but most of them lack details. In this study, we aimed to investigate the association of statin use with glycaemic traits and incident type 2 diabetes. METHODS: Using the prospective population-based Rotterdam Study, we included 9535 individuals free from diabetes at baseline (>45 years) during the study period between 1997 and 2012. Linear regression analysis was applied to examine the cross-sectional associations between statin use and glycaemic traits including fasting blood serum of glucose and insulin concentrations, and insulin resistance. In a longitudinal follow-up study, we applied a Cox regression analysis to determine adjusted hazard ratios (HR) for incident type 2 diabetes in new users of statins. RESULTS: The mean age at baseline was 64.3 ± 10.1 years and 41.7% were men. In the fully adjusted model, compared to never users of statins, baseline use of statins was associated with higher concentrations of serum fasting insulin (β = 0.07; 95% CI: 0.02-0.13) and insulin resistance (β = 0.09; 95% CI: 0.03-0.14). Ever use of statins was associated with a 38% higher risk of incident type 2 diabetes (HR = 1.38; 95% CI: 1.09-1.74). This risk was more prominent in subjects with impaired glucose homeostasis and in overweight/obese individuals. CONCLUSIONS: Individuals using statins may be at higher risk for hyperglycaemia, insulin resistance and eventually type 2 diabetes. Rigorous preventive strategies such as glucose control and weight reduction in patients when initiating statin therapy might help minimize the risk of diabetes.
AIMS: There are several epidemiological studies on the association between statins and incident diabetes, but most of them lack details. In this study, we aimed to investigate the association of statin use with glycaemic traits and incident type 2 diabetes. METHODS: Using the prospective population-based Rotterdam Study, we included 9535 individuals free from diabetes at baseline (>45 years) during the study period between 1997 and 2012. Linear regression analysis was applied to examine the cross-sectional associations between statin use and glycaemic traits including fasting blood serum of glucose and insulin concentrations, and insulin resistance. In a longitudinal follow-up study, we applied a Cox regression analysis to determine adjusted hazard ratios (HR) for incident type 2 diabetes in new users of statins. RESULTS: The mean age at baseline was 64.3 ± 10.1 years and 41.7% were men. In the fully adjusted model, compared to never users of statins, baseline use of statins was associated with higher concentrations of serum fasting insulin (β = 0.07; 95% CI: 0.02-0.13) and insulin resistance (β = 0.09; 95% CI: 0.03-0.14). Ever use of statins was associated with a 38% higher risk of incident type 2 diabetes (HR = 1.38; 95% CI: 1.09-1.74). This risk was more prominent in subjects with impaired glucose homeostasis and in overweight/obese individuals. CONCLUSIONS: Individuals using statins may be at higher risk for hyperglycaemia, insulin resistance and eventually type 2 diabetes. Rigorous preventive strategies such as glucose control and weight reduction in patients when initiating statin therapy might help minimize the risk of diabetes.
Authors: M Arfan Ikram; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Stricker; Henning Tiemeier; André G Uitterlinden; Meike W Vernooij; Albert Hofman Journal: Eur J Epidemiol Date: 2017-10-24 Impact factor: 8.082
Authors: Estela Lorza-Gil; Alessandro G Salerno; Amarylis C B A Wanschel; Jean F Vettorazzi; Mônica S Ferreira; Thiago Rentz; Rodrigo R Catharino; Helena C F Oliveira Journal: Toxicology Date: 2016-02-10 Impact factor: 4.221
Authors: Annie L Culver; Ira S Ockene; Raji Balasubramanian; Barbara C Olendzki; Deidre M Sepavich; Jean Wactawski-Wende; Joann E Manson; Yongxia Qiao; Simin Liu; Philip A Merriam; Catherine Rahilly-Tierny; Fridtjof Thomas; Jeffrey S Berger; Judith K Ockene; J David Curb; Yunsheng Ma Journal: Arch Intern Med Date: 2012-01-09
Authors: Eliano Pio Navarese; Antonino Buffon; Felicita Andreotti; Marek Kozinski; Nicky Welton; Tomasz Fabiszak; Salvatore Caputo; Grzegorz Grzesk; Aldona Kubica; Iwona Swiatkiewicz; Adam Sukiennik; Malte Kelm; Stefano De Servi; Jacek Kubica Journal: Am J Cardiol Date: 2013-01-24 Impact factor: 2.778
Authors: Daniel J Sansome; Karen L Jones; Michael Horowitz; Christopher K Rayner; Tongzhi Wu Journal: Br J Clin Pharmacol Date: 2020-03-30 Impact factor: 4.335
Authors: Fahim Abbasi; Cindy Lamendola; Chelsea S Harris; Vander Harris; Ming-Shian Tsai; Pragya Tripathi; Fakhar Abbas; Gerald M Reaven; Peter D Reaven; Michael P Snyder; Sun H Kim; Joshua W Knowles Journal: Arterioscler Thromb Vasc Biol Date: 2021-08-26 Impact factor: 8.311
Authors: M Arfan Ikram; Guy Brusselle; Mohsen Ghanbari; André Goedegebure; M Kamran Ikram; Maryam Kavousi; Brenda C T Kieboom; Caroline C W Klaver; Robert J de Knegt; Annemarie I Luik; Tamar E C Nijsten; Robin P Peeters; Frank J A van Rooij; Bruno H Stricker; André G Uitterlinden; Meike W Vernooij; Trudy Voortman Journal: Eur J Epidemiol Date: 2020-05-04 Impact factor: 8.082
Authors: Sean J Jurgens; Seung Hoan Choi; Valerie N Morrill; Mark Chaffin; James P Pirruccello; Jennifer L Halford; Lu-Chen Weng; Victor Nauffal; Carolina Roselli; Amelia W Hall; Matthew T Oetjens; Braxton Lagerman; David P vanMaanen; Krishna G Aragam; Kathryn L Lunetta; Christopher M Haggerty; Steven A Lubitz; Patrick T Ellinor Journal: Nat Genet Date: 2022-02-17 Impact factor: 41.307
Authors: Petra Czarniak; Fariba Ahmadizar; Jeff Hughes; Richard Parsons; Maryam Kavousi; Mohammad Ikram; Bruno H Stricker Journal: Br J Clin Pharmacol Date: 2021-12-28 Impact factor: 3.716
Authors: Min Yan Shi; In Hyuk Bang; Chang Yeob Han; Dae Ho Lee; Byung-Hyun Park; Eun Ju Bae Journal: Theranostics Date: 2020-09-15 Impact factor: 11.556